Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 + T-lymphocyte counts.
CNS oncology（2018）
摘要
The addition of ERC1671/GM-CSF/cyclophosphamide to bevacizumab resulted in a clinically meaningful survival benefit with minimal additional toxicity.
更多查看译文
关键词
CD4+ T lymphocyte,ERC1671,GBM,GBM vaccine,allogeneic,autologous,bevacizumab,glioma surgery,immunotherapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要